Elevated Galectin-3 levels in the tumor microenvironment of ovarian cancer – implication of ROS mediated suppression of NK cell antitumor response via tumor-associated neutrophils DOI Creative Commons
Veronika Karlsson,

Ebba Stål,

Emma Stoopendahl

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 20, 2024

Ovarian cancer is a lethal disease with low survival rates for women diagnosed in advanced stages. Current immunotherapies are not efficient ovarian cancer, and there therefore significant need novel treatment options. The β-galactoside-binding lectin, Galectin-3, involved different immune processes has been associated poor outcome various diagnoses. Here, we investigated how Galectin-3 affects the interaction between natural killer (NK) cells neutrophils tumor microenvironment of cancer.

Language: Английский

Assessment of Anticancer Properties of Thai Plants DOI
Bancha Yingngam

Advances in medical diagnosis, treatment, and care (AMDTC) book series, Journal Year: 2024, Volume and Issue: unknown, P. 122 - 164

Published: March 11, 2024

Cancer, a critical health concern, necessitates safer, more effective treatments. This chapter explores the anticancer potential of traditional Thai plants, which, despite being underresearched, show significant promise. It focuses on bioactive compounds and their efficacy against various cancer types. The categorizes these plants based active components reviews both laboratory animal studies to understand underlying mechanisms involved in inhibiting cell growth, inducing death, preventing tumor blood vessel formation. Clinical trials supporting findings are also highlighted. Given improve or innovate treatments, present encouraging prospects. However, further research is essential confirm safety approaches. These suggest that could lead development innovative drugs, signaling advancements therapy.

Language: Английский

Citations

13
Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises DOI Creative Commons

Sara Bandini,

Paola Ulivi, Tania Rossi

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(4), P. 337 - 337

Published: Feb. 13, 2024

Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of cancer, in particular lung while introduction predictive biomarkers from liquid biopsies emerged as a promising tool to achieve an effective and personalized response. Important progress also been made molecular characterization extracellular vesicles (EVs) circulating tumor cells (CTCs), highlighting their tremendous potential modulating microenvironment, acting on immunomodulatory pathways, setting up pre-metastatic niche. Surface antigens EVs CTCs have proved be particularly useful case immune escape mechanisms through expression immunosuppressive ligands or transport cargos that may mitigate antitumor function. On other hand, novel approaches, increase immunostimulatory molecules cargo contents can enhance response, offer premium options combinatorial clinical strategies for precision immunotherapy. In this review, we discuss recent advances identification checkpoints using CTCs, applications ICI therapy, prospective use innovative tools, considering already approved by Food Drug Administration (FDA) use, but providing good reasons intensify research both.

Language: Английский

Citations

8
A comprehensive prognostic and immune analysis of LAPTM4B in pan-cancer and Philadelphia chromosome-positive acute lymphoblastic leukemia DOI Creative Commons
Hui Zhou,

Yuyao Yi,

Wei He

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 28, 2025

Introduction Lysosomal-associated protein transmembrane-4 beta (LAPTM4B) expression was increased in solid tumors, whereas few studies were performed hematologic malignancies. We aimed to study the effect of LAPTM4B gene pan-cancer and Philadelphia chromosome-positive acute B cell lymphoblastic leukemia (Ph+ B-ALL). Methods The differential expression, diagnosis, prognosis, genetic epigenetic alterations, tumor microenvironment, stemness, immune infiltration cells, function enrichment, single-cell analysis, drug response across cancers conducted based on multiple computational tools. Additionally, Ph+ B-ALL transgenic mouse model with Laptm4b knockout used analyze vivo . BrdU incorporation method, flow cytometry, Witte-lock Witte culture evaluate roles vitro Results identified that various cancers, significant associations clinical outcomes. correlated DNA RNA methylation patterns associated resistance. It also influenced implications for immunotherapy response. In leukemia, expressed stem cells specific subtypes. Knockout impeded progression mice reduced proliferation caused G0/G1 arrest Discussion Our elucidated role promoted development B-ALL. Furthermore, played a diagnostic, prognostic, immunological factor.

Language: Английский

Citations

0
Therapeutic effects of NK cell-derived EVs on cancer: Current advances and future treatment strategies DOI
Mehtap Kızılpınar, Mohammadreza Dastourı

Published: Jan. 1, 2025

Cancer remains a leading cause of death globally, with conventional treatments such as surgery, chemotherapy, and radiotherapy offering limited success, especially in advanced stages or cases metastatic resistant tumors. As result, there is pressing need for novel therapeutic approaches. Immunotherapy has emerged promising alternative, natural killer (NK) cells playing central role due to their ability selectively target kill cancer while sparing healthy tissues. This review explores the potential NK cell-derived extracellular vesicles (NK-EVs), innovation treatment. NK-EVs, including exosomes, carry bioactive molecules proteins, lipids, RNA that can influence tumor surrounding immune microenvironment. The examines various sources biological functions, mechanisms through which they exert effects, focusing on both membrane content proteins. These play crucial modulation, enhancing responses promoting apoptosis cells. Additionally, NK-EVs have gained attention carriers delivering agents, chemotherapeutic drugs, small interfering RNAs (siRNAs), microRNAs (miRNAs), providing approach overcoming limitations traditional therapies, poor drug delivery resistance. also highlights recent advances NK-EV production, bioreactor-based systems stress-induced EV generation, are essential scaling up use clinical applications. Furthermore, we discuss immunotherapeutic effects exosomes (Exos), methods assessing cytotoxicity, serve effective targeted therapy. By reviewing current advancements future strategies, this article provides comprehensive outlook tool fight against cancer, pathways more therapies.

Language: Английский

Citations

0
Liver Transplantation for Non-Hepatocellular Carcinoma: Role of Immune Checkpoint Inhibitors DOI

Pegah Bahrami,

Mohammad Al Zein,

Ali H. Eid

et al.

Journal of Clinical and Experimental Hepatology, Journal Year: 2025, Volume and Issue: unknown, P. 102558 - 102558

Published: March 1, 2025

Language: Английский

Citations

0
Promising New Anti‐TIGIT Agents: Stealthy Allies in Cancer Immunotherapy DOI Creative Commons
G. Srikanth,

Durga Prasad Beda,

Ashish Ranjan Dwivedi

et al.

Clinical and Translational Science, Journal Year: 2025, Volume and Issue: 18(4)

Published: April 1, 2025

ABSTRACT TIGIT (T cell immunoreceptor with immunoglobulin and tyrosine‐based inhibitory motif (ITIM) domain), Vstm3, VSIG9, are newly recognized immunological checkpoints. They prominently expressed on CD4+ CD8+ T cells, tumor‐infiltrating lymphocytes (TILs), natural killer (NK) regulatory cells (Tregs). The (TIGIT) protein is crucial for immune modulation since it diminishes NK populations hinders activity in cancer patients experimental models. CD155, the principal ligand of humans, has been as a pivotal target immunotherapy owing to its interaction TIGIT. CD155 linked efficacy anti‐programmed death 1 (PD‐1) therapy, even without expression, underscoring importance checkpoint suppression. Anti‐TIGIT medicines, either independently or conjunction anti‐PD‐1 treatments, have demonstrated potential augmenting responses malignancies. This review examines structural functional characteristics protein, new developments anti‐TIGIT drugs, their prospective use immunotherapy.

Language: Английский

Citations

0
Immune-Related Adverse Events in Immunotherapy: Challenges in Diagnosis, Monitoring, and Management DOI Creative Commons
Mohd Aftab Siddiqui, Afreen Usmani, Mohd Nazam Ansari

et al.

Toxicology Reports, Journal Year: 2025, Volume and Issue: 14, P. 102036 - 102036

Published: April 23, 2025

Language: Английский

Citations

0
Immune checkpoint blocking in cancer therapy using thermosensitive hydrogels: a review DOI

Vahid Tayebi-Khorrami,

Mohammad Reza Fadaei,

Shiva Fallahianshafiei

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: May 2, 2025

Language: Английский

Citations

0
Boosting CAR-T cell therapy with CRISPR technology DOI Creative Commons
Liyanran Yan,

Shanzi Gao,

Xinhui Wang

et al.

hLife, Journal Year: 2024, Volume and Issue: 2(8), P. 380 - 396

Published: June 9, 2024

Chimeric antigen receptor (CAR)-T cell therapy has made remarkable breakthroughs in treating cancers, especially hematologic malignancies, yet its broader application cancer treatment is hindered by multiple challenges. Meanwhile, the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and derived technologies provided unprecedentedly efficient tools for genomic cellular reprogramming, offering potential advantages developing CAR-T therapy. There hence a rapidly increasing interest applying CRISPR to engineer cells. Here, we present review recent research utilizing boost enhancing safety or effectiveness. We first provide an overview technology, followed discussions on how related can be adopted tackle various issues associated with therapy, either via knockout/knockin specific genes CRISPR-based screening. also summarize clinical trials involving CRISPR-edited Lastly, address risks engineering.

Language: Английский

Citations

2
Editorial for the Special Issue “Advances in the Development of Anticancer Drugs” DOI Open Access
Jean Fotie

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(1), P. 641 - 641

Published: Jan. 4, 2024

As mortality rates for other leading causes of death, such as stroke and coronary heart disease, decline in many parts the world, cancer is becoming cause death worldwide, with number yearly new cases expected to rise about 30 million by 2040 [...]

Language: Английский

Citations

1